Abstract | OBJECTIVE: This study examined whether first-trimester antifungal drug use was associated with the risk of selected birth defects. STUDY DESIGN: Subjects were participants in a case-control study, the National Birth Defects Prevention Study, with singleton deliveries from 1997 to 2003. Based on maternal interviews, first-trimester antifungal drug use was compared between 7047 cases with isolated defects and 4774 nonmalformed controls using unconditional logistic regression. RESULTS: CONCLUSION:
|
Authors | Tonia C Carter, Charlotte M Druschel, Paul A Romitti, Erin M Bell, Martha M Werler, Allen A Mitchell, National Birth Defects Prevention Study |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 198
Issue 2
Pg. 191.e1-7
(Feb 2008)
ISSN: 1097-6868 [Electronic] United States |
PMID | 18226621
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Abnormalities, Drug-Induced
(epidemiology, etiology)
- Antifungal Agents
(administration & dosage, adverse effects)
- Candidiasis, Vulvovaginal
(drug therapy)
- Case-Control Studies
- Female
- Heart Defects, Congenital
(epidemiology, etiology)
- Humans
- Hypoplastic Left Heart Syndrome
(chemically induced, epidemiology)
- Infant, Newborn
- Pregnancy
- Pregnancy Complications, Infectious
(drug therapy)
- Pregnancy Trimester, First
- Registries
- Risk Factors
- United States
(epidemiology)
|